Cationic Lipids for Serum-Resistant Nucleic Acid Transfection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current lipid-based delivery systems for nucleic acids are hindered by the inhibitory effects of serum components, limiting their effectiveness both in vitro and in vivo, especially in achieving high levels of transfection required for therapeutic applications.

Innovation Solution

Development of novel lipids, as described by various formulas (I-XVI), which form compounds suitable for use in pharmaceutical compositions, lipid aggregates, and liposomes, enabling efficient delivery of nucleic acids to cells even in the presence of serum.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional lipid-based delivery systems are used, then nucleic acid delivery is achieved under low-serum or serum-free conditions, but transfection efficiency is limited in the presence of serum

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidactivity in presence of serum

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies the chemical parameters of lipid molecules by introducing specific structural features (cationic headgroups, unsaturated hydrocarbon chains with multiple double bonds, specific chain lengths) to create novel lipids that maintain transfection activity in serum-containing environments, directly resolving the contradiction between transfection efficiency and serum compatibility

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite lipid structures combining multiple functional components (charged nitrogen-containing groups, unsaturated hydrocarbon chains, specific linker moieties) within single lipid molecules to achieve both high transfection efficiency and resistance to serum inhibition simultaneously

Inventive Principle:

Principle #40Composite materials

2Reliability

If higher levels of transfection are achieved, then therapeutic effect is improved, but amount of material required increases potential toxicities

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

By optimizing the chemical parameters of the lipid molecules (charge density, hydrophobicity, molecular weight, unsaturation level), the patent achieves high transfection efficiency at lower material concentrations, thereby reducing the dose required and minimizing potential toxic effects while maintaining therapeutic effectiveness

Inventive Principle:

Principle #35Parameter changes

3Productivity

If conventional lipids are used for nucleic acid delivery, then delivery to cells is achieved, but activity is inhibited by serum components

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidserum inhibition

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent incorporates cationic (positively charged) groups into the lipid structure, which interact favorably with the anionic (negatively charged) nucleic acids and cell membranes, converting the potentially harmful interaction with serum components into a beneficial mechanism that protects the nucleic acid payload and enhances cellular uptake, thereby maintaining delivery efficiency in serum-containing environments

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12344572B2Cationic lipids and transfection methods

Publication Date: 2025.07.01 FACTOR BIOSCIENCE INC

AI summary

The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.